Verrica Pharmaceuticals (VRCA) Net Cash Flow (2017 - 2026)
Verrica Pharmaceuticals (VRCA) posted quarterly Net Cash Flow of -$9.3 million for Q1 2026, up 44.31% year-over-year from -$6.5 million in Q1 2025, and down 203.09% quarter-over-quarter from $9.0 million in Q4 2025.
Verrica Pharmaceuticals (VRCA) Net Cash Flow (2017 - 2026) Analysis & Trends
Verrica Pharmaceuticals' Net Cash Flow history runs 10 years deep, the most recent figure standing at -$9.3 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 44.31% year-over-year to -$9.3 million; the TTM figure through Mar 2026 stood at -$8.7 million (up 54.81% YoY), while the FY2025 annual figure was -$16.2 million, up 30.42% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$9.3 million, down from $9.0 million in the prior quarter.
- The five-year high for Net Cash Flow was $34.7 million in Q1 2022, with the low at -$20.6 million in Q1 2024.
- The 5-year median for Net Cash Flow is -$5.0 million (2022), against an average of $300117.6.
- Peak annual rise in Net Cash Flow reached 325.11% in 2023, while the deepest fall reached 920.06% in 2023.
- Verrica Pharmaceuticals' Net Cash Flow stood at $1.8 million in 2022, then tumbled by 920.06% to -$14.8 million in 2023, then soared by 258.32% to $23.4 million in 2024, then sank by 61.31% to $9.0 million in 2025, then plunged by 203.09% to -$9.3 million in 2026.
- Business Quant data shows VRCA's Net Cash Flow at -$9.3 million in Q1 2026, $9.0 million in Q4 2025, and $5.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Verrica Pharmaceuticals | 102.80 Mn | 91.60 Mn | - | -9.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.37 Mn |
| Jun 30, 2026 | -9.37 Mn |
| Mar 31, 2026 | -9.32 Mn |
| Mar 31, 2026 | -9.32 Mn |
| Dec 31, 2025 | 9.04 Mn |
| Dec 31, 2025 | 9.04 Mn |
| Sep 30, 2025 | 5.74 Mn |
| Sep 30, 2025 | 5.74 Mn |
| Jun 30, 2025 | -14.20 Mn |
| Jun 30, 2025 | -14.20 Mn |
| Mar 31, 2025 | -16.73 Mn |
| Mar 31, 2025 | -16.73 Mn |
| Dec 31, 2024 | 23.37 Mn |
| Dec 31, 2024 | 23.37 Mn |
| Sep 30, 2024 | -8.97 Mn |
| Sep 30, 2024 | -8.97 Mn |
| Jun 30, 2024 | -17.01 Mn |
| Jun 30, 2024 | -17.01 Mn |
| Mar 31, 2024 | -20.61 Mn |
| Mar 31, 2024 | -20.61 Mn |